Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoXSWX:LLY +4.71%25 3-Year Dividend Growth Rate is 15.20% as of Jun. 2026, which is 97% above its 10-year median of 7.70. GuruFocus rates XSWX:LLY with a GF Score™ of 25/100 and a GF Value™ of CHF1,225.10 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 350 Drug Manufacturers companies, Eli Lilly and Co ranks better than 64% on this metric.
The historical rank and industry rank for Eli Lilly and Co's 3-Year Dividend Growth Rate or its related term are showing as below:
XSWX:LLY'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0 Med: 7.7 Max: 20.2
Current: 15.2
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Eli Lilly and Co was 20.20% per year. The lowest was 0.00% per year. And the median was 7.70% per year.
XSWX:LLY's 3-Year Dividend Growth Rate is ranked better than 64% of 350
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs XSWX:LLY: 15.20
During the past 12 months, Eli Lilly and Co's average Dividends Per Share Growth Rate was 15.40% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 15.20% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 15.20% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Eli Lilly and Co was 0.72. The lowest was 0.21. And the median was 0.44.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Eli Lilly and Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 1.730000
2026-05-15
2026-05-15
2026-06-10
Cash Dividend
quarterly
USD:CHF 0.781100
USD 1.730000
2026-02-13
2026-02-13
2026-03-10
Cash Dividend
quarterly
USD:CHF 0.768600
USD 1.500000
2025-11-14
2025-11-14
2025-12-10
Cash Dividend
quarterly
USD:CHF 0.803478
USD 1.500000
2025-08-15
2025-08-15
2025-09-10
Cash Dividend
quarterly
USD:CHF 0.813367
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Eli Lilly and Co's Dividend Yield (%) for Today is calculated as
Current Share Price is CHF1000.00.
Eli Lilly and Co's Dividends per Share for the trailing twelve months (TTM) ended in Today is CHF5.1062485.
During the past 13 years, the highest Dividend Yield of Eli Lilly and Co was 3.00%. The lowest was 0.51%. And the median was 1.38%.
Warning Sign:
Eli Lilly and Co stock Dividend Yield % is close to 10-year low.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co 3-Year Dividend Growth Rate Related Terms>
XSWX:LLY vs JNJ, ABBV, MRK: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's 3-Year Dividend Growth Rate falls into.
Eli Lilly and Co 3-Year Dividend Growth Rate Calculation
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 15.20% mean?
Eli Lilly and Co (XSWX:LLY) has a 3-Year Dividend Growth Rate of 15.20% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Eli Lilly and Co and its competitors. This is 97% above median its historical median of 7.70. According to the industry distribution chart, Eli Lilly and Co ranks #126 out of 350 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is Eli Lilly and Co's 3-Year Dividend Growth Rate too high?
Eli Lilly and Co's current 3-Year Dividend Growth Rate of 15.20% is 97% above median its 10-year median of 7.70. The Drug Manufacturers industry median 3-Year Dividend Growth Rate is 7.70. Eli Lilly and Co's value of 15.20% is 97.4% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #126 out of 350 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 25/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's 3-Year Dividend Growth Rate compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #126 out of 350 companies for 3-Year Dividend Growth Rate. This puts Eli Lilly and Co in the upper half of its industry. The industry median 3-Year Dividend Growth Rate is 7.70. Eli Lilly and Co's value of 15.20% is 97.4% above this benchmark. While the company's 10-year median is 7.70 vs. the industry median of 7.70, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current 3-Year Dividend Growth Rate of 15.20% is 97.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current 3-Year Dividend Growth Rate is 15.20%, which is 97% above median its own 10-year median of 7.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,225.10, compared to a current price of CHF1,000.00 — trading 18.4% below its estimated fair value. The current 3-Year Dividend Growth Rate is 15.20%, which is 97% above median its 10-year median of 7.70 and 97.4% above the Drug Manufacturers industry median of 7.70. Eli Lilly and Co's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current 3-Year Dividend Growth Rate is 15.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF1,000.00 is trading 18.4% below its estimated GF Value™ of CHF1,225.10.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
3-Year Dividend Growth Rate: 15.20% (97% above median its 10-year median of 7.70)
GF Value™: CHF1,225.10 vs. price of CHF1,000.00 (18.4% below fair value)
Industry Position: 97.4% above the Drug Manufacturers median (#126 of 350)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
25GF Score
Get the complete analysis for XSWX:LLY
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
